Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 11/20 | 0.46 |
| ▸ | IRAK1 | P51617 | 7/20 | 0.45 |
| ▸ | CCNC | P24863 | 2/20 | 0.45 |
| ▸ | CDK8 | P49336 | 2/20 | 0.45 |
| ▸ | WNT1 | P04628 | 2/20 | 0.44 |
| ▸ | GSK3B | P49841 | 2/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15416231 | 0.99 | IRAK4 (0.47) | IRAK4IRAK1CCNCCDK8WNT1 | |
| SCHEMBL15416724 | 0.97 | IRAK4 (0.47) | IRAK4IRAK1CCNCCDK8GRIN2B | |
| SCHEMBL15431484 | 0.92 | CCNC (0.52) | IRAK4IRAK1CCNCCDK8WNT1 | |
| Hydrochloric Acid SCHEMBL16713467 | 0.91 | CCNC (0.52) | IRAK4IRAK1CCNCCDK8WNT1 | |
| SCHEMBL15431497 | 0.91 | IRAK4 (0.47) | IRAK4IRAK1CCNCCDK8WNT1 | |
| SCHEMBL15431569 | 0.90 | IRAK4 (0.49) | IRAK4IRAK1CCNCCDK8WNT1 | |
| SCHEMBL15431644 | 0.90 | CCNC (0.47) | CCNCCDK8GRIN2B | |
| SCHEMBL15431493 | 0.90 | SPR (0.50) | IRAK4IRAK1 | |
| SCHEMBL15416381 | 0.90 | CCNC (0.47) | CCNCCDK8GRIN2B | |
| Hydrochloric Acid SCHEMBL15416693 | 0.89 | CCNC (0.46) | CCNCCDK8GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2872501-B1 | PYRIMIDINE PYRAZOLYL DERIVATIVES | ARES TRADING SA (CH) | 2016-06-01 | — | — | EP | claimed |
| US-9216991-B2 | Pyrimidine pyrazolyl derivatives | ARES TRADING S.A. (CH) | 2015-12-22 | — | — | US | claimed |
| US-20150141396-A1 | PYRIMIDINE PYRAZOLYL DERIVATIVES | ARES TRADING S.A. (CH) | 2015-05-21 | — | — | US | claimed |
| EP-2872501-B1 | PYRIMIDINE PYRAZOLYL DERIVATIVES | ARES TRADING SA (CH) | 2016-06-01 | — | — | EP | disclosed |
| EP-2872501-B1 | PYRIMIDINE PYRAZOLYL DERIVATIVES | ARES TRADING SA (CH) | 2016-06-01 | — | — | EP | disclosed |
| US-9216991-B2 | Pyrimidine pyrazolyl derivatives | ARES TRADING S.A. (CH) | 2015-12-22 | — | — | US | disclosed |
| US-9216991-B2 | Pyrimidine pyrazolyl derivatives | ARES TRADING S.A. (CH) | 2015-12-22 | — | — | US | disclosed |
| US-9216991-B2 | Pyrimidine pyrazolyl derivatives | ARES TRADING S.A. (CH) | 2015-12-22 | — | — | US | disclosed |
| EP-2877524-A2 | METHOD FOR CHEMICAL FOAMING IN THE PRESENCE OF REINFORCING FILLERS | Rhodia Operations (FR) | 2015-06-03 | — | — | EP | disclosed |
| US-20150141396-A1 | PYRIMIDINE PYRAZOLYL DERIVATIVES | ARES TRADING S.A. (CH) | 2015-05-21 | — | — | US | disclosed |
| US-20150141396-A1 | PYRIMIDINE PYRAZOLYL DERIVATIVES | ARES TRADING S.A. (CH) | 2015-05-21 | — | — | US | disclosed |
| US-20150141396-A1 | PYRIMIDINE PYRAZOLYL DERIVATIVES | ARES TRADING S.A. (CH) | 2015-05-21 | — | — | US | disclosed |
| EP-2872501-A1 | PYRIMIDINE PYRAZOLYL DERIVATIVES | Ares Trading S.A. (CH) | 2015-05-20 | — | — | EP | disclosed |
| WO-2014008992-A1 | PYRIMIDINE PYRAZOLYL DERIVATIVES | ARES TRADING S.A. (CH) | 2014-01-16 | — | — | WO | disclosed |
| WO-2014009540-A2 | METHOD FOR CHEMICAL FOAMING IN THE PRESENCE OF REINFORCING FILLERS | RHODIA OPERATIONS (FR) | 2014-01-16 | — | — | WO | disclosed |
| WO-2014008992-A1 | PYRIMIDINE PYRAZOLYL DERIVATIVES | ARES TRADING S.A. (CH) | 2014-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141396-A1 | PYRIMIDINE PYRAZOLYL DERIVATIVES | DPYD, TYMS, DHFR | IRAK4 75/4885IRAK1 117/4885CCNC 1085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.